Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP

Thehuman internal dosimetry of the radionuclidic impurities of samarium-153 in a new bone-seeking radiopharmaceutical, (153)Sm-1,4,7,10tetraazacyclododecanetetramethylenephosponic acid ((153)Sm-DOTMP), has been estimated from preclinical data. The effective dose from the impurities in lower-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Wendt, Richard E., Ketring, Alan R., Frank, R. Keith, Simón, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896376/
https://www.ncbi.nlm.nih.gov/pubmed/35452906
http://dx.doi.org/10.1016/j.apradiso.2022.110246
Descripción
Sumario:Thehuman internal dosimetry of the radionuclidic impurities of samarium-153 in a new bone-seeking radiopharmaceutical, (153)Sm-1,4,7,10tetraazacyclododecanetetramethylenephosponic acid ((153)Sm-DOTMP), has been estimated from preclinical data. The effective dose from the impurities in lower-specific-activity (153)Sm is less than 17% of the effective dose from pure Sm-153. It has a background-equivalent radiation time for a dosage of 37 MBq/kg of less than one-half year.

Ejemplares similares